Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an update.
BioArctic AB announced that the Therapeutic Goods Administration (TGA) of Australia has approved Leqembi® for treating early Alzheimer’s disease in specific patient groups. This approval marks a significant milestone following a review process initiated by Eisai, BioArctic’s partner, after an initial rejection. The approval strengthens BioArctic’s and Eisai’s position in the Alzheimer’s treatment market, allowing them to expand their commercialization efforts, particularly in the Nordic region.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharma company specializing in innovative treatments for neurodegenerative diseases. The company is known for inventing Leqembi® (lecanemab), a drug that slows the progression of early Alzheimer’s disease. BioArctic collaborates with Eisai for global commercialization and regulatory interactions, and it also has a diverse research portfolio targeting Parkinson’s disease, ALS, and other Alzheimer’s treatments.
Average Trading Volume: 301,781
Technical Sentiment Signal: Buy
Current Market Cap: SEK25.28B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.